TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative stress of plates. The placebo-controlled double blind design study included 1708, randomized to EDTA + vitamins, EDTA + placebo, placebo + vitamins o placebo + placebo. Primary end point was a composite of death, infarction, revascularization and hospitalization for angina, with a 60 month follow up. The group EDTA vs. placebo showed less events (33% vs. 38% respectively p=0,03).

Conclusión: the administration of 40 EDTA sessions was safe and effective.

Comment: though it has a number of methodological limitations (such as a 20% follow up loss) and because the physiological mechanism of the EDTA effect remains unknown, this study should be considered as a hypothesis generator

Gervasio Lamas
2012-11-04

Original title: Results of the Trial to Assess Chelation Therapy (TACT Trial) 

More articles by this author

TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.

TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel...

FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at...

CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.

A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were...

Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...